CXCL12 and breast carcinoma: Interestingly, in breast cancer cells the synthesis and release of CXCL12 is under the control of 17β-estradiol contributing to its proliferative effects and mediating, via a Src-dependent mechanism, EGFR transactivation [133, 154].